Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB680 Combination Therapy in Advanced Pancreatic Cancer
NCT04104672Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Nov 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quemliclustat in pancreatic cancer (PC) (7 arms), sponsored by Arcus Biosciences. Primary endpoints: Treatment Emergent Adverse Events up to 1 year and Dose Limiting Toxicities at day 28. Started Nov 2019; status: completed.
02
Drugs
quemliclustat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04104672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104672.